{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:40:27Z","timestamp":1788306027796,"version":"build-2803163510"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T00:00:00Z","timestamp":1487289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2017,5]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n \n Anti\u2013tumor necrosis factor alpha (\n TNF<\/jats:styled-content>\n \u2010\u03b1) agents are used to treat a variety of autoimmune and inflammatory conditions, including psoriasis. Paradoxically, numerous reports have documented new\u2010onset or exacerbation of psoriasis or psoriasiform skin lesions (\n PSO<\/jats:styled-content>\n ) in patients treated with these agents for conditions other than PSO\u2014particularly in adults with inflammatory bowel disease (\n IBD<\/jats:styled-content>\n ). Not much is known regarding similar cases in children.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A retrospective chart review was performed on children younger than 19 years of age with\n IBD<\/jats:styled-content>\n seen at the Mayo Clinic between 2003 and 2015 who developed new\u2010onset or recurrent\n PSO<\/jats:styled-content>\n while undergoing anti\u2010\n TNF<\/jats:styled-content>\n \u2010\u03b1 therapy.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Fourteen children developed PSO while undergoing anti\u2010\n TNF<\/jats:styled-content>\n \u2010\u03b1 therapy for\n IBD<\/jats:styled-content>\n . All three anti\u2010\n TNF<\/jats:styled-content>\n \u2010\u03b1 agents (infliximab, adalimumab, certolizumab) used to treat\n IBD<\/jats:styled-content>\n in this series led to induction or recurrence of PSO lesions. The median time to development of\n PSO<\/jats:styled-content>\n was 11\u00a0months (range 0\u201348 mos), the median age was 15\u00a0years (range 12.5\u201317.5\u00a0yrs), and 57% of patients were male.\n IBD<\/jats:styled-content>\n activity was quiescent in 93% of cases at\n PSO<\/jats:styled-content>\n onset. Seven patients (50%) discontinued their initial anti\u2010\n TNF<\/jats:styled-content>\n \u2010\u03b1 therapy because of their skin disease. Ultimately, four patients (29%) had to discontinue all anti\u2010\n TNF<\/jats:styled-content>\n \u2010\u03b1 therapy to induce\n PSO<\/jats:styled-content>\n resolution.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n TNF<\/jats:styled-content>\n \u2010\u03b1 antagonist\u2013induced PSO in children with\n IBD<\/jats:styled-content>\n is a rarely reported adverse reaction.\n PSO<\/jats:styled-content>\n onset has a variable latency, but usually occurs during\n IBD<\/jats:styled-content>\n remission, with a slight male bias. Nearly half of patients required a change in their initial anti\u2010\n TNF<\/jats:styled-content>\n \u2010\u03b1 agent despite conventional skin\u2010directed therapies, and one\u2010third of patients discontinued all anti\u2010\n TNF<\/jats:styled-content>\n \u2010\u03b1 therapy because of\n PSO<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/pde.13081","type":"journal-article","created":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T00:26:40Z","timestamp":1487291200000},"page":"253-260","source":"Crossref","is-referenced-by-count":55,"title":["Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti\u2013Tumor Necrosis Factor Alpha Agents"],"prefix":"10.1111","volume":"34","author":[{"given":"Joshua B.","family":"Eickstaedt","sequence":"first","affiliation":[{"name":"Division of Hospital Internal Medicine Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Killpack","sequence":"additional","affiliation":[{"name":"LewisGale Hospital Montgomery Blacksburg Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Tung","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology and Hepatology Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Dermatology Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Hand","sequence":"additional","affiliation":[{"name":"Department of Dermatology Mayo Clinic Rochester Minnesota"},{"name":"Department of Clinical Genomics Mayo Clinic Rochester Minnesota"},{"name":"Department of Pediatrics and Adolescent Medicine Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha M.","family":"Tollefson","sequence":"additional","affiliation":[{"name":"Department of Dermatology Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,17]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90398-0"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.03031.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.540"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302853"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087288"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2011.01521.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.049916"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2010.01267.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anpedi.2008.11.013"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31828390ba"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000088"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200809010-00001"},{"key":"e_1_2_6_14_1","first-page":"380","article-title":"Psoriasis induced by tumor necrosis factor\u2010\u03b1 antagonist therapy: a case series","volume":"34","author":"Cohen JD","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04866.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062897"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.07.029"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630802441234"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.205"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.08.007"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.2.223"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23923.x"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpde.13081","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.13081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T21:57:15Z","timestamp":1696197435000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.13081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,17]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1111\/pde.13081"],"URL":"https:\/\/doi.org\/10.1111\/pde.13081","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727350170.793568145","asserted-by":"object"}]},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,17]]}}}